Interim 2022 results: oodles of progress
We have changed our forecasts and valuation to reflect both a lower spend than we had anticipated, and the predicted $10m (now £8.7m) licensing transaction before YE 2022.Cash at the end of H1 2022 was £8.4m, (£7.1m at H1 2021), reflecting the recent fundraising and the lower H1 R&D spend than we had estimated, and provides a runway until at least mid-2023. Our YE 2022 estimate of cash is £12.1m, which includes our expectations of a licensing transaction.
The results release summarises the developments on pipeline, discussions with the regulators on its two Phase 3-ready assets, and what appears to be an accelerating pace of partnering activities: particularly on NTCD-M3. The attractiveness of these assets to licensing partners should have been increased by Destiny’s efforts.
Our valuation has risen from £209.6m (288p/share) to £251.2m (345p/share).
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.